Skip to main content

Preclinical Development of GZ30-1, A Novel Chemoprotectant

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
Nov 19, 2012
Award amount: 
Organization name: 
G1 Therapeutics
Principal Investigator: 
Black, Claudia A
Grant program category: 
Business Financing
Grant program name: 
Strategic Growth Loan
Research Triangle

Myelosuppression represents the major dose-limiting toxicity of cancer chemotherapy, resulting in considerable morbidity and mortality along with frequent reductions in chemotherapy dose intensity, which may compromise disease control and survival. Protection from DNA-damaging chemotherapy provided to the HSPC by GZ30-1 will minimize the major dose-limiting side-effects of current SCLC therapies

Fiscal year: